Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELU |
---|---|---|
09:32 ET | 141 | 3.05 |
09:34 ET | 100 | 3.03 |
09:36 ET | 275 | 3.03 |
09:38 ET | 100 | 3.04 |
09:41 ET | 100 | 3.04 |
09:45 ET | 100 | 3.03 |
09:52 ET | 100 | 3.03 |
09:54 ET | 100 | 3.03 |
09:56 ET | 100 | 3.03 |
09:57 ET | 158 | 3.03 |
09:59 ET | 100 | 3 |
10:01 ET | 100 | 3 |
10:03 ET | 100 | 3 |
10:08 ET | 100 | 3 |
10:10 ET | 100 | 2.99 |
10:12 ET | 100 | 2.99 |
10:14 ET | 100 | 2.99 |
10:17 ET | 100 | 2.99 |
10:21 ET | 100 | 2.95 |
10:26 ET | 100 | 2.93 |
10:28 ET | 200 | 2.89 |
10:30 ET | 206 | 2.88 |
10:33 ET | 100 | 2.88 |
10:35 ET | 100 | 2.88 |
10:39 ET | 1118 | 2.88 |
10:44 ET | 100 | 2.88 |
10:46 ET | 100 | 2.88 |
10:48 ET | 100 | 2.89 |
10:51 ET | 100 | 2.89 |
10:53 ET | 100 | 2.89 |
10:55 ET | 100 | 2.89 |
11:00 ET | 100 | 2.89 |
11:02 ET | 100 | 2.89 |
11:04 ET | 100 | 2.89 |
11:06 ET | 200 | 2.89 |
11:09 ET | 100 | 2.89 |
11:13 ET | 100 | 2.89 |
11:22 ET | 100 | 2.89 |
11:26 ET | 100 | 2.88 |
11:27 ET | 100 | 2.88 |
11:29 ET | 100 | 2.88 |
11:31 ET | 100 | 2.88 |
11:36 ET | 100 | 2.88 |
11:38 ET | 100 | 2.88 |
11:40 ET | 100 | 2.88 |
11:42 ET | 202 | 2.8963 |
11:44 ET | 100 | 2.88 |
11:47 ET | 100 | 2.88 |
11:51 ET | 100 | 2.88 |
11:54 ET | 100 | 2.88 |
11:56 ET | 100 | 2.88 |
12:00 ET | 100 | 2.88 |
12:05 ET | 100 | 2.88 |
12:12 ET | 100 | 2.89 |
12:14 ET | 100 | 2.89 |
12:18 ET | 100 | 2.89 |
12:20 ET | 100 | 2.89 |
12:21 ET | 100 | 2.9 |
12:23 ET | 100 | 2.91 |
12:27 ET | 100 | 2.91 |
12:30 ET | 200 | 2.91 |
12:36 ET | 300 | 3 |
12:38 ET | 100 | 2.93 |
12:39 ET | 100 | 2.92 |
12:43 ET | 100 | 2.91 |
12:45 ET | 100 | 2.91 |
12:48 ET | 100 | 2.91 |
12:50 ET | 100 | 2.91 |
12:56 ET | 100 | 2.91 |
12:57 ET | 100 | 2.91 |
01:01 ET | 100 | 2.91 |
01:03 ET | 100 | 2.91 |
01:06 ET | 100 | 2.91 |
01:10 ET | 100 | 2.91 |
01:12 ET | 100 | 2.91 |
01:14 ET | 100 | 2.91 |
01:15 ET | 100 | 2.91 |
01:19 ET | 100 | 2.91 |
01:21 ET | 100 | 2.91 |
01:24 ET | 100 | 2.91 |
01:26 ET | 430 | 2.8801 |
01:28 ET | 100 | 2.91 |
01:30 ET | 100 | 2.91 |
01:32 ET | 200 | 2.91 |
01:37 ET | 100 | 2.91 |
01:39 ET | 100 | 2.91 |
01:42 ET | 100 | 2.91 |
01:46 ET | 100 | 2.91 |
01:48 ET | 100 | 2.91 |
01:50 ET | 100 | 2.91 |
01:53 ET | 100 | 2.91 |
01:55 ET | 100 | 2.91 |
01:57 ET | 100 | 2.91 |
02:02 ET | 100 | 2.91 |
02:04 ET | 100 | 2.91 |
02:06 ET | 100 | 2.91 |
02:08 ET | 100 | 2.91 |
02:11 ET | 100 | 2.91 |
02:13 ET | 100 | 2.91 |
02:15 ET | 100 | 2.91 |
02:22 ET | 100 | 2.91 |
02:24 ET | 100 | 2.91 |
02:27 ET | 100 | 2.91 |
02:29 ET | 100 | 2.91 |
02:31 ET | 1100 | 2.9743 |
02:33 ET | 100 | 2.91 |
02:38 ET | 100 | 2.91 |
02:40 ET | 100 | 2.91 |
02:45 ET | 100 | 2.91 |
02:47 ET | 100 | 2.91 |
02:49 ET | 100 | 2.91 |
02:54 ET | 100 | 2.91 |
02:56 ET | 100 | 2.91 |
02:58 ET | 100 | 2.91 |
03:00 ET | 100 | 2.92 |
03:07 ET | 100 | 2.91 |
03:09 ET | 100 | 2.935 |
03:14 ET | 200 | 2.91 |
03:20 ET | 100 | 2.91 |
03:21 ET | 100 | 2.91 |
03:23 ET | 100 | 2.91 |
03:25 ET | 100 | 2.935 |
03:30 ET | 100 | 2.91 |
03:32 ET | 100 | 2.91 |
03:34 ET | 100 | 2.91 |
03:36 ET | 500 | 2.91 |
03:38 ET | 400 | 2.91 |
03:39 ET | 500 | 2.91 |
03:41 ET | 200 | 2.89 |
03:48 ET | 400 | 2.87 |
03:50 ET | 400 | 2.87 |
03:52 ET | 300 | 2.87 |
03:54 ET | 400 | 2.86 |
03:56 ET | 1059 | 2.86 |
03:57 ET | 300 | 2.86 |
03:59 ET | 300 | 2.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celularity Inc | 64.0M | -0.3x | --- |
Gritstone bio Inc | 63.0M | -0.4x | --- |
Turnstone Biologics Corp | 51.8M | -0.6x | --- |
Carisma Therapeutics Inc | 47.8M | -0.6x | --- |
Prenetics Global Ltd | 73.1M | -1.4x | --- |
ImmuCell Corp | 33.4M | -8.5x | --- |
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $64.0M |
---|---|
Revenue (TTM) | $14.8M |
Shares Outstanding | 21.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-10.51 |
Book Value | $13.36 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 4.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,272.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.